PD Neurotrophin/GDNF Delivery Companies

Parkinson's Disease Neurotrophin/GDNF Delivery Companies

Overview

Neurotrophin delivery represents one of the most promising approaches for Parkinson's disease therapy, aiming to provide trophic support to vulnerable dopaminergic neurons in the substantia nigra pars compacta. The Glial Cell Line-Derived Neurotrophic Factor (GDNF) family—including GDNF, Neurturin (NRTN), Artemin (ARTN), and Persephin (PSPN)—has demonstrated potent neuroprotective effects on dopaminergic neurons in preclinical models. However, delivering these proteins to the central nervous system remains a significant challenge due to their inability to cross the blood-brain barrier and their short half-life in systemic circulation.

This page catalogs biotechnology and pharmaceutical companies developing therapies to deliver neurotrophic factors to the Parkinson's disease brain, including gene therapy approaches, cell-based delivery systems, protein engineering, and novel delivery technologies.

Market Landscape

The neurotrophin delivery field for Parkinson's disease has evolved through several generations of technology:

• First Generation (1990s-2000s): Direct protein infusion into the brain via intracerebral catheters
• Second Generation (2000s-2010s): AAV-mediated gene therapy for sustained local expression
• Third Generation (2010s-present): Cell-based therapies, engineered proteins, and novel viral vectors

Parkinson's Disease Neurotrophin/GDNF Delivery Companies

Overview

Neurotrophin delivery represents one of the most promising approaches for Parkinson's disease therapy, aiming to provide trophic support to vulnerable dopaminergic neurons in the substantia nigra pars compacta. The Glial Cell Line-Derived Neurotrophic Factor (GDNF) family—including GDNF, Neurturin (NRTN), Artemin (ARTN), and Persephin (PSPN)—has demonstrated potent neuroprotective effects on dopaminergic neurons in preclinical models. However, delivering these proteins to the central nervous system remains a significant challenge due to their inability to cross the blood-brain barrier and their short half-life in systemic circulation.

This page catalogs biotechnology and pharmaceutical companies developing therapies to deliver neurotrophic factors to the Parkinson's disease brain, including gene therapy approaches, cell-based delivery systems, protein engineering, and novel delivery technologies.

Market Landscape

The neurotrophin delivery field for Parkinson's disease has evolved through several generations of technology:

• First Generation (1990s-2000s): Direct protein infusion into the brain via intracerebral catheters
• Second Generation (2000s-2010s): AAV-mediated gene therapy for sustained local expression
• Third Generation (2010s-present): Cell-based therapies, engineered proteins, and novel viral vectors

Key Companies

Gene Therapy Approaches

1. uniQure N.V.

| Attribute | Value |
|-----------|-------|
| Headquarters | Amsterdam, Netherlands / Lexington, Massachusetts |
| Ticker | QURE (NASDAQ) |
| Founded | 2000 |
| Focus | AAV gene therapy |

uniQure has developed a proprietary AAV gene therapy platform and has applied it to various neurological indications. The company has explored GDNF delivery for Parkinson's disease through academic partnerships, leveraging their high-capacity AAV vector technology for sustained expression of neurotrophic factors in the striatum.

Technology Platform:

• Proprietary AAV5 and AAVhu.68 vectors
• Industrial-scale manufacturing capabilities
• Proprietary miRNA targeting technology for reduced off-target expression

• Research-stage GDNF gene therapy collaboration programs
• Focus on optimizing delivery to dopaminergic neurons

2. Voyager Therapeutics

| Attribute | Value |
|-----------|-------|
| Headquarters | Cambridge, Massachusetts |
| Ticker | VYTR (NASDAQ) |
| Founded | 2013 |
| Focus | CNS gene therapy |

Voyager Therapeutics focuses on AAV-mediated gene therapy for neurological disorders. While their lead PD program (VY-AADC) delivers the AADC enzyme to restore dopamine synthesis, the company has explored additional targets for neuroprotection including approaches to support dopaminergic neuron survival.

Pipeline Relevance:

• VY-AADC: Addresses dopamine restoration rather than neuroprotection
• Platform applicable to neurotrophin delivery approaches
• Strategic partnerships with neurotech companies

3. ID Pharma Co., Ltd.

| Attribute | Value |
|-----------|-------|
| Headquarters | Tokyo, Japan |
| Founded | 2003 |
| Focus | AAV and lentiviral vectors |

ID Pharma is a Japanese biotechnology company specializing in viral vector development and manufacturing. The company has active programs in GDNF and Neurturin delivery for Parkinson's disease[@idpharma].

Programs:

| Program | Target | Stage | Description |
|---------|--------|-------|-------------|
| AAV-GDNF | Parkinson's disease | Preclinical | GDNF gene delivery to striatum |
| AAV-Neurturin | Parkinson's disease | Research | Neurturin expression for neuroprotection |

Capabilities:

• cGMP manufacturing facilities in Japan
• Proprietary AAV production systems
• Academic partnerships with Japanese universities

Cell-Based Delivery

4. BrainStorm Cell Therapeutics Inc.

| Attribute | Value |
|-----------|-------|
| Headquarters | New York, New York, USA |
| Ticker | BCLI (NASDAQ) |
| Founded | 2000 |
| Focus | Autologous MSC cell therapy |

BrainStorm's NurOwn® platform represents a cell-based approach to neurotrophin delivery. The therapy uses the patient's own bone marrow-derived mesenchymal stromal cells (MSCs) that are engineered to secrete elevated levels of neurotrophic factors including GDNF, BDNF, VEGF, and HGF[@brainstorm].

Technology:

• Cell Source: Autologous bone marrow-derived MSCs
• Process: Proprietary culture conditions induce neurotrophic factor secretion
• Delivery: Intrathecal injection into cerebrospinal fluid
• Advantage: Immune-privileged autologous cells, sustained factor release

| Program | Indication | Phase | Status |
|---------|------------|-------|--------|
| NurOwn | ALS | Phase 3 | Completed |
| NurOwn | Progressive MS | Phase 1 | Active |
| NurOwn | Alzheimer's disease | Preclinical | Planning |
| NurOwn | Parkinson's disease | Research | Exploratory |

Clinical Evidence:

• Phase 3 ALS trial showed subgroup benefits in less advanced disease
• Demonstrated safety across multiple indications
• MSC-NTF cells secrete functional GDNF and BDNF

5. Living Cell Technologies (LCT)

| Attribute | Value |
|-----------|-------|
| Headquarters | Sydney, Australia |
| Ticker | LCT (ASX) |
| Founded | 2007 |
| Focus | Encapsulated cell therapy |

Living Cell Technologies developed NTCELL, an encapsulated cell therapy for Parkinson's disease that provides neurotrophic support through transplanted choroid plexus cells[@lct].

Technology:

• Encapsulation: Semi-permeable membrane allows diffusion of neurotrophic factors
• Cell Source: Porcine-derived choroid plexus cells
• Delivery: Stereotactic implantation into the brain
• Advantage: Immune isolation enables allogeneic cells without immunosuppression

| Trial | Phase | Status | Results |
|-------|-------|--------|---------|
| NTCELL-001 | Phase 1/2a | Completed | Primary endpoint met |
| NTCELL-002 | Phase 2b | Planned | Trial design in review |

Clinical Outcomes:

• Improvements in OFF-medication UPDRS motor scores
• Reduced levodopa-induced dyskinesias in some patients
• Sustained effects observed up to 5 years post-implantation

6. Hope Biomedical

| Attribute | Value |
|-----------|-------|
| Focus | Cell therapy for CNS disorders |

Hope Biomedical has developed cell-based approaches for CNS delivery of therapeutic proteins. The company focuses on engineering cells to secrete neurotrophic factors for neurodegenerative disease applications.

Protein Delivery Technologies

7. PharmaEssentia Corporation

| Attribute | Value |
|-----------|-------|
| Headquarters | Taipei, Taiwan / Boston, Massachusetts |
| Ticker | 6589 (TPEx) / PHCE (NASDAQ) |
| Founded | 2003 |
| Focus | Protein therapeutics |

PharmaEssentia has explored protein-based approaches to neurotrophin delivery, leveraging their protein engineering capabilities to develop stable, bioactive neurotrophic factor formulations.

Approach:

• Engineered GDNF protein variants with improved stability
• Delivery optimization for CNS targeting
• Focus on protein half-life extension

AAV Vector Companies with CNS Programs

8. 4D Molecular Therapeutics

| Attribute | Value |
|-----------|-------|
| Headquarters | Emeryville, California |
| Ticker | FDMT (NASDAQ) |
| Founded | 2014 |
| Focus | AAV vector engineering |

4DMT develops next-generation AAV vectors with improved CNS tropism and delivery characteristics. While primarily a vector platform company, their technology enables partners to develop neurotrophin delivery programs.

Platform:

• Directed evolution for tissue-specific capsids
• Proprietary R100 delivery platform
• Enhanced brain penetration

9. REGENXBIO Inc.

| Attribute | Value |
|-----------|-------|
| Headquarters | Rockville, Maryland |
| Ticker | RGNX (NASDAQ) |
| Founded | 2009 |
| Focus | AAV gene therapy |

REGENXBIO provides AAV vector technology through licensing and partnerships. Their NAV Technology Platform has been applied to various CNS programs, including neurotrophin delivery approaches.

Technology:

• NAV AAV vectors (AAV7, AAV8, AAV9, AAVrh.10)
• Licensed to multiple partners for CNS programs
• Manufacturing platform for clinical-scale production

Historical Programs

Cerevel/AbbVie (CERE-120)

Cerevel Therapeutics (formerly part of Pfizer, now AbbVie) developed CERE-120 (AAV-NRTN), a gene therapy delivering neurturin to the Parkinson's disease brain. The program completed clinical trials:

• Phase 1/2: Demonstrated safety and suggested efficacy
• Phase 3: Did not meet primary endpoint in advanced PD patients
• Status: Program was discontinued but data informed future approaches

Technology Comparison

Delivery Modalities

| Technology | Advantages | Disadvantages | Stage |
|------------|------------|---------------|-------|
| AAV Gene Therapy | Sustained expression, single dose | Irreversible, immune response | Clinical |
| Cell Encapsulation | Retrievable, sustained release | Surgical implantation | Clinical |
| MSC Cell Therapy | Autologous, immune-privileged | Variable cell function | Clinical |
| Protein Infusion | Tunable dosing | Short half-life, BBB crossing | Historic |
| Exosomes/Nanoparticles | BBB crossing potential | Early stage | Preclinical |

Target Comparison

| Factor | Primary Receptor | Target Neurons | Clinical Stage |
|--------|------------------|----------------|----------------|
| GDNF | GFRα1/RET | Dopaminergic, motor | Clinical |
| Neurturin | GFRα2/RET | Dopaminergic, sensory | Clinical (discontinued) |
| BDNF | TrkB | Multiple CNS neurons | Research |
| Artemin | GFRα3/RET | Sensory, sympathetic | Preclinical |
| Persephin | GFRα4/RET | Motor neurons | Preclinical |

Clinical Trial Landscape

Active and Recent Trials

| Company | Therapy | Identifier | Phase | Status |
|---------|---------|------------|-------|--------|
| BrainStorm | NurOwn | NCT03280056 | Phase 3 | Completed |
| LCT | NTCELL | ACTRN12615000216549 | Phase 1/2a | Completed |
| Various | AAV-GDNF | Various | Phase 1/2 | Various |

Historical Trials

| Program | Company | Years | Outcome |
|---------|---------|-------|---------|
| Intracerebral GDNF | Various | 1999-2009 | Mixed results, side effects |
| CERE-120 (AAV-NRTN) | Cerevel/Pfizer | 2008-2019 | Phase 3 did not meet endpoint |
| AAV-GDNF (AAV2) | Various | 2010s | Ongoing |

Research and Development Challenges

Delivery Challenges

Biological Challenges

Regulatory Challenges

Emerging Approaches

Novel Delivery Technologies

• Exosome-mediated delivery: Engineered exosomes for CNS targeting
• Focused ultrasound: BBB opening for enhanced protein delivery
• Intranasal delivery: Non-invasive neurotrophin delivery
• Nanoparticle carriers: Targeted CNS delivery systems

Next-Generation Gene Therapy

• Regulatable expression: Small molecule-controlled GDNF levels
• Cell-type specific promoters: Targeting specific neuronal populations
• Novel serotypes: Improved brain tropism
• Gene editing: Precise integration of therapeutic genes

Combination Approaches

• Neurotrophin + α-synuclein targeting: Combined neuroprotection and disease modification
• GDNF + AADC: Dopamine restoration plus neuroprotection
• Cell therapy + gene therapy: Enhanced trophic support

Investment and Partnership Landscape

Key Partnerships

| Company | Partner | Focus | Value |
|---------|---------|-------|-------|
| Voyager | NeuroPace | VY-AADC | Various |
| LCT | DIatherix | Development | Various |
| ID Pharma | Multiple | Vector manufacturing | Various |

Market Opportunity

• Parkinson's disease affects approximately 10 million people worldwide
• Current treatments address symptoms but not disease progression
• Neurotrophin therapy represents potential disease-modifying approach
• Addressable market in billions of dollars

See Also

• [GDNF Signaling Pathway](/mechanisms/gdnf-signaling-pathway)
• [Neurotrophic Signaling](/mechanisms/neurotrophic-signaling-pathway)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Gene Therapy for Neurodegeneration](/mechanisms/aav-gene-therapy-vectors-neurodegeneration)
• [Cell Therapy for Neurodegeneration](/companies/ad-cell-therapy-companies)
• [Dopaminergic Neurons](/cell-types/dopaminergic-neurons)

References